GIHCG and neoplasm: GIHCG was first described in hepatocellular carcinoma, where it was demonstrated to enhance tumor cell proliferation, migration, and metastases both in vitro and in vivo by recruiting the transcription factors EZH2 and DNMT1 to the miR-200b/a/429 promoter, thereby epigenetically silencing miR-200b/a/429 expression (Sui et al., 2016).